Your browser doesn't support javascript.
loading
Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results.
Kuramitsu, Madoka; Sekizuka, Tsuyoshi; Yamochi, Tadanori; Firouzi, Sanaz; Sato, Tomoo; Umeki, Kazumi; Sasaki, Daisuke; Hasegawa, Hiroo; Kubota, Ryuji; Sobata, Rieko; Matsumoto, Chieko; Kaneko, Noriaki; Momose, Haruka; Araki, Kumiko; Saito, Masumichi; Nosaka, Kisato; Utsunomiya, Atae; Koh, Ki-Ryang; Ogata, Masao; Uchimaru, Kaoru; Iwanaga, Masako; Sagara, Yasuko; Yamano, Yoshihisa; Okayama, Akihiko; Miura, Kiyonori; Satake, Masahiro; Saito, Shigeru; Itabashi, Kazuo; Yamaguchi, Kazunari; Kuroda, Makoto; Watanabe, Toshiki; Okuma, Kazu; Hamaguchi, Isao.
Afiliação
  • Kuramitsu M; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Sekizuka T; Pathogen Genomic Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Yamochi T; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Firouzi S; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Sato T; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Umeki K; Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
  • Sasaki D; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Hasegawa H; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Kubota R; Division of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Sobata R; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Matsumoto C; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Kaneko N; Department of Special Testing, SRL Inc., Tokyo, Japan.
  • Momose H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Araki K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Saito M; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nosaka K; Department of Hematology, Kumamoto University of Medicine, Kumamoto, Japan.
  • Utsunomiya A; Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
  • Koh KR; Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
  • Ogata M; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
  • Uchimaru K; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Iwanaga M; Department of Hematology and Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Sagara Y; Department of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Yamano Y; Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
  • Okayama A; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Miura K; Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
  • Satake M; Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Saito S; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Itabashi K; Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
  • Yamaguchi K; Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
  • Kuroda M; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Watanabe T; Pathogen Genomic Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Okuma K; Department of Advanced Medical Innovation, Graduate School of Medicine, St. Marianna University, Kawasaki, Japan.
  • Hamaguchi I; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
J Clin Microbiol ; 55(9): 2838-2849, 2017 09.
Article em En | MEDLINE | ID: mdl-28701419
ABSTRACT
Western blotting (WB) for human T cell leukemia virus type 1 (HTLV-1) is performed to confirm anti-HTLV-1 antibodies detected at the initial screening of blood donors and in pregnant women. However, the frequent occurrence of indeterminate results is a problem with this test. We therefore assessed the cause of indeterminate WB results by analyzing HTLV-1 provirus genomic sequences. A quantitative PCR assay measuring HTLV-1 provirus in WB-indeterminate samples revealed that the median proviral load was approximately 100-fold lower than that of WB-positive samples (0.01 versus 0.71 copy/100 cells). Phylogenic analysis of the complete HTLV-1 genomes of WB-indeterminate samples did not identify any specific phylogenetic groups. When we analyzed the nucleotide changes in 19 HTLV-1 isolates from WB-indeterminate samples, we identified 135 single nucleotide substitutions, composed of four types, G to A (29%), C to T (19%), T to C (19%), and A to G (16%). In the most frequent G-to-A substitution, 64% occurred at GG dinucleotides, indicating that APOBEC3G is responsible for mutagenesis in WB-indeterminate samples. Moreover, interestingly, five WB-indeterminate isolates had nonsense mutations in Pol and/or Tax, Env, p12, and p30. These findings suggest that WB-indeterminate carriers have low production of viral antigens because of a combination of a low proviral load and mutations in the provirus, which may interfere with host recognition of HTLV-1 antigens.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Infecções por HTLV-I / Provírus / Anticorpos Antivirais Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: J Clin Microbiol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Infecções por HTLV-I / Provírus / Anticorpos Antivirais Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: J Clin Microbiol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão